Recent research advancements indicate that atopic dermatitis (AD) is a complex disease
characterized by different subtypes/phenotypes based on age, disease chronicity, ethnicity …

With an increasing prevalence during the past decades, atopic dermatitis has become a
global health issue. A literature search following a targeted approach was undertaken to …

Background Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced
atopic dermatitis (AD) severity in a phase II study with concomitant topical corticosteroids …

Background Dupilumab is an IL-4 receptor α mAb inhibiting signaling of IL-4 and IL-13, key
drivers of type 2–driven inflammation, as demonstrated by its efficacy in patients with …

Background There are gaps in our knowledge of the prevalence of adult atopic dermatitis
(AD). Objective To estimate the prevalence of AD in adults and by disease severity. Methods …

Background The patient burden and quality of life (QOL) impact of atopic dermatitis (AD) in
the United States population is not well established. Objective To elucidate the patient …

Progress in understanding of the mechanisms underlying chronic inflammatory skin
disorders, such as atopic dermatitis and psoriasis vulgaris, has led to new treatment options …

An estimated 20–25% of the population is affected by chronic, non-communicable
inflammatory skin diseases. Chronic skin inflammation has many causes. Among the most …

Atopic dermatitis (AD), the most common chronic inflammatory skin disease, is driven by
both terminal keratinocyte differentiation defects and strong type 2 immune responses. In …

Importance Adolescents with atopic dermatitis (AD) have high disease burden negatively
affecting quality of life, with limited treatment options. The efficacy and safety of dupilumab, a …